AlloVir

Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for prevalent retinal diseases, particularly those with significant unmet medical needs. Their lead product, TH103, is an investigational biologic designed to improve patient outcomes in conditions such as wet AMD, diabetic eye disease, an... d retinal vein occlusion by reducing the burden of frequent clinic visits. The company aims to enhance the efficacy and durability of anti-VEGF therapies, leveraging the expertise of its experienced management team and scientific founders. Kalaris is currently conducting clinical trials to evaluate TH103's potential and plans to expand its research into other VEGF-mediated retinal diseases.Read More